[Bufexamac cream and ointment for the treatment of various dermatoses].
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003872:Dermatitis / Q000188:drug therapy*; D003876:Dermatitis, Atopic / Q000188:drug therapy; D003877:Dermatitis, Contact / Q000188:drug therapy; D004361:Drug Tolerance; D004485:Eczema / Q000188:drug therapy; D005069:Evaluation Studies as Topic; D005446:Fluocinolone Acetonide / Q000627:therapeutic use; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage* / Q000627:therapeutic use; D007627:Keloid / Q000188:drug therapy; D009824:Ointments; D010648:Phenylacetates / Q000008:administration & dosage / Q000627:therapeutic use; D010689:Phlebitis / Q000188:drug therapy; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D006877:Hydroxamic Acids; D009824:Ointments; D010648:Phenylacetates; D005446:Fluocinolone Acetonide
Etude du bufexamac crème et du bufexamac onguent dans le traitement de diverses dermatoses.